Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCENT-J02: Sacituzumab Govitecan in Japanese Patients With Advanced Solid Tumors
NCT05101096Phase 2Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Oct 2021
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab govitecan in solid tumor (advanced stage), triple-negative breast cancer (TNBC), breast cancer, urothelial carcinoma (UC), sponsored by Gilead Sciences. Started Oct 2021; status: active, not recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
solid tumor (advanced stage)triple-negative breast cancer (TNBC)breast cancerurothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT05101096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05101096.